Soufflé Therapeutics raises $135 million to develop three RNA medicines
read at Endpoints ↗DealPositive
Soufflé Therapeutics, a biotech with ties to MIT professor Bob Langer, announced a new financing round.
The round raised $135 million from venture capital investors.
The capital will be used to advance at least three experimental oligonucleotide (RNA) medicines.
The funding underscores investor confidence in RNA based therapeutics and supports the company's development pipeline.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Soufflé gets $135M for three RNA medicines”
read at Endpoints ↗80 words · retrieved 27m ago
comments(0)
5-min edit window · permanent after that